Comparison · NCT03136445-8869f132
Intervention Arm vs Control Arm: Number of Participants With a Thrombotic Event From First Administration of Trial Treatment up to and Including 120 Days After the First Dose of Trial Treatment is Received (N)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention Arm vs Control Arm: Number of Participants With a Thrombotic Event From First Administration of Trial Treatment up to and Including 120 Days After the First Dose of Trial Treatment is Received (N). Trial comparisons, record NCT03136445-8869f132. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03136445-8869f132
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0267 | 0.0136 | 0.0517 | wilson | |
| Risk in group 2 | 0.0168 | 0.00721 | 0.0388 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00983 | -0.0157 | 0.0367 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.58 | 0.524 | 4.79 | log | |
| Odds ratio, group 1 over group 2 | 1.6 | 0.517 | 4.95 | log | |
| Number needed to treat, for one more participant with the outcome on Intervention Arm than on Control Arm | 102 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention Arm | Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.~Tranexamic acid (TXA).: IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid. | 8 | 300 | OG000 |
| Group 2 | Control Arm | Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.~Placebo: IV (saline) or oral placebo tablets | 5 | 297 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Thrombotic Event From First Administration of Trial Treatment up to and Including 120 Days After the First Dose of Trial Treatment is Received (N)
- Description
- Measured by calculating number of patients developing clinically diagnosed thrombotic events within 120 days of Treatment Day 1 i.e the first day that the IMP is administered.
- Time frame
- Up to and including 120 days from the first administration of investigational medicinal product (IMP).
- Population
Source ClinicalTrials.gov
Trial
- Title
- TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
- NCT number
- NCT03136445
- Phases
- PHASE3
- Conditions
- Hematologic Neoplasms, Hemorrhage, Hematopoietic Stem Cell Transplantation
- Interventions
- Tranexamic acid (TXA)., Placebo
- Lead sponsor
- NHS Blood and Transplant
- Results first posted
- 2025-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03136445?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03136445-8869f132